Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias

US11951090B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• UNIVERSITÉ PARIS CITÉ · FR
• Moraine Corporation · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• UNIVERSIDAD DE GRANADA · ES

Inventors

• Laurence LEGEAI-MALLET · Paris, FR
• Antonio Segura Carretero · Granada, ES
• Maria De La Luz Cadiz Gurrea · Granada, ES

Key dates

• Filing date: Jan 23, 2019
• Grant date: Apr 9, 2024
• Expiry date: Nov 25, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P19/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin from T. cacao and showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.